Ipsen SA
PAR:IPN

Watchlist Manager
Ipsen SA Logo
Ipsen SA
PAR:IPN
Watchlist
Price: 111.3 EUR 2.02% Market Closed
Market Cap: 9.2B EUR
Have any thoughts about
Ipsen SA?
Write Note

Intrinsic Value

The intrinsic value of one IPN stock under the Base Case scenario is 148.83 EUR. Compared to the current market price of 111.3 EUR, Ipsen SA is Undervalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPN Intrinsic Value
148.83 EUR
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ipsen SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IPN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IPN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Ipsen SA

Provide an overview of the primary business activities
of Ipsen SA.

What unique competitive advantages
does Ipsen SA hold over its rivals?

What risks and challenges
does Ipsen SA face in the near future?

Has there been any significant insider trading activity
in Ipsen SA recently?

Summarize the latest earnings call
of Ipsen SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ipsen SA.

Provide P/S
for Ipsen SA.

Provide P/E
for Ipsen SA.

Provide P/OCF
for Ipsen SA.

Provide P/FCFE
for Ipsen SA.

Provide P/B
for Ipsen SA.

Provide EV/S
for Ipsen SA.

Provide EV/GP
for Ipsen SA.

Provide EV/EBITDA
for Ipsen SA.

Provide EV/EBIT
for Ipsen SA.

Provide EV/OCF
for Ipsen SA.

Provide EV/FCFF
for Ipsen SA.

Provide EV/IC
for Ipsen SA.

Show me price targets
for Ipsen SA made by professional analysts.

What are the Revenue projections
for Ipsen SA?

How accurate were the past Revenue estimates
for Ipsen SA?

What are the Net Income projections
for Ipsen SA?

How accurate were the past Net Income estimates
for Ipsen SA?

What are the EPS projections
for Ipsen SA?

How accurate were the past EPS estimates
for Ipsen SA?

What are the EBIT projections
for Ipsen SA?

How accurate were the past EBIT estimates
for Ipsen SA?

Compare the revenue forecasts
for Ipsen SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ipsen SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ipsen SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ipsen SA compared to its peers.

Compare the P/E ratios
of Ipsen SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Ipsen SA with its peers.

Analyze the financial leverage
of Ipsen SA compared to its main competitors.

Show all profitability ratios
for Ipsen SA.

Provide ROE
for Ipsen SA.

Provide ROA
for Ipsen SA.

Provide ROIC
for Ipsen SA.

Provide ROCE
for Ipsen SA.

Provide Gross Margin
for Ipsen SA.

Provide Operating Margin
for Ipsen SA.

Provide Net Margin
for Ipsen SA.

Provide FCF Margin
for Ipsen SA.

Show all solvency ratios
for Ipsen SA.

Provide D/E Ratio
for Ipsen SA.

Provide D/A Ratio
for Ipsen SA.

Provide Interest Coverage Ratio
for Ipsen SA.

Provide Altman Z-Score Ratio
for Ipsen SA.

Provide Quick Ratio
for Ipsen SA.

Provide Current Ratio
for Ipsen SA.

Provide Cash Ratio
for Ipsen SA.

What is the historical Revenue growth
over the last 5 years for Ipsen SA?

What is the historical Net Income growth
over the last 5 years for Ipsen SA?

What is the current Free Cash Flow
of Ipsen SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ipsen SA.

Business Breakdown

Ipsen SA is a dynamic biopharmaceutical group based in France that has carved a significant niche in the global healthcare landscape. Founded in 1929, the company has evolved into a key player in the development of innovative medicines specializing in oncology, neuroscience, and rare diseases. With a strong commitment to research and development, Ipsen aims to address unmet medical needs by delivering transformative treatments. Its robust pipeline includes promising products that have garnered attention for their potential impact on patient outcomes, particularly in cancer therapies and treatments for debilitating conditions such as severe muscle spasms. Investors find Ipsen compelling due t...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ipsen SA

Current Assets 1.9B
Cash & Short-Term Investments 493.5m
Receivables 761.2m
Other Current Assets 645.1m
Non-Current Assets 4.6B
Long-Term Investments 141.4m
PP&E 594.2m
Intangibles 3.6B
Other Non-Current Assets 348.6m
Current Liabilities 1.7B
Accounts Payable 857.6m
Short-Term Debt 17.9m
Other Current Liabilities 789.7m
Non-Current Liabilities 835.1m
Long-Term Debt 351.3m
Other Non-Current Liabilities 483.8m
Efficiency

Earnings Waterfall
Ipsen SA

Revenue
3.4B EUR
Cost of Revenue
-618m EUR
Gross Profit
2.8B EUR
Operating Expenses
-2.2B EUR
Operating Income
586.5m EUR
Other Expenses
94.7m EUR
Net Income
681.2m EUR

Free Cash Flow Analysis
Ipsen SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IPN Profitability Score
Profitability Due Diligence

Ipsen SA's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive Operating Income
62/100
Profitability
Score

Ipsen SA's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

IPN Solvency Score
Solvency Due Diligence

Ipsen SA's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
High Altman Z-Score
Long-Term Solvency
79/100
Solvency
Score

Ipsen SA's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPN Price Targets Summary
Ipsen SA

Wall Street analysts forecast IPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPN is 129.4 EUR with a low forecast of 111.1 EUR and a high forecast of 171.15 EUR.

Lowest
Price Target
111.1 EUR
0% Downside
Average
Price Target
129.4 EUR
16% Upside
Highest
Price Target
171.15 EUR
54% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IPN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for IPN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IPN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Ipsen SA Logo
Ipsen SA

Country

France

Industry

Pharmaceuticals

Market Cap

9.2B EUR

Dividend Yield

1.08%

Description

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Contact

ILE-DE-FRANCE
Boulogne-Billancourt
65 Quai Georges Gorse
+33158335000.0
www.ipsen.com

IPO

2005-12-06

Employees

5 703

Officers

MD, CEO & Director
Mr. David Loew
Executive VP & CFO
Mr. Aymeric Le Chatelier
Executive VP and Head of Technical Operations
Dr. Aidan Murphy Ph.D.
Vice-President of Investor Relations
Mr. Craig Marks
Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer
Mr. Francois Garnier
Executive VP & Chief Human Resources Officer
Mr. Regis Mulot
Show More
Head of Nordics & Baltics
Ms. Dominique Bery
Executive VP and Head of Global Product & Portfolio Strategy
Mr. Bartosz Bednarz D.D.S.
Executive VP & Chief Business Officer
Mr. Philippe Lopes-Fernandes CBO
President of Fondation Ipsen
Dr. James Levine M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IPN stock?

The intrinsic value of one IPN stock under the Base Case scenario is 148.83 EUR.

Is IPN stock undervalued or overvalued?

Compared to the current market price of 111.3 EUR, Ipsen SA is Undervalued by 25%.

Back to Top